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Study Highlights WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
þ Lack of knowledge of the target-site concentrations in the CNS is a major hurdle in the development of new CNS drugs.
WHAT QUESTION DID THIS STUDY ADDRESS?
þ A generic PBPK model in the rat CNS was proposed. WHAT THIS STUDY ADDS TO OUR KNOWLEDGE þ The developed PBPK model was able to predict time-dependent concentration profiles of many drugs with distinctively different physicochemical properties in multiple physiologically relevant compartments in the CNS. HOW MIGHT THIS CHANGE DRUG DISCOVERY, DEVELOPMENT, AND/OR THERAPEUTICS? þ The developed model structure can be used to predict concentration-time profiles in rats and offers a scientific basis for the development of CNS drugs, in principle, without the need of using animals.
The development of drugs targeting diseases of the central nervous system (CNS) represents one of the most significant challenges in the research of new medicines. 1 Characterization of exposure-response relationships at the drug target site may be of critical importance to reduce attrition. However, unlike for many other drugs, prediction of targetsite concentrations for CNS drugs is complex, among other factors, due to the presence of the blood-brain barrier (BBB) and the blood-cerebrospinal fluid barrier (BCSFB). Moreover, direct measurement of human brain concentrations is highly restricted for ethical reasons. Therefore, new approaches that can robustly predict human brain concentrations of novel drug candidates based on in vitro and in silico studies are of great importance.
Several pharmacokinetic (PK) models to predict CNS exposure have been published with different levels of complexity. 2 The majority of these models depend on animal data. Furthermore, these models have typically not been validated against human CNS drug concentrations. 2 We previously published a general multicompartmental CNS PK model structure, which was developed using PK data obtained from rats.
Quantitative structure-property relationship (QSPR) models can be used to predict drug BBB permeability and Kp,uu,brain ECF (unbound brain extracellular fluid-to-plasma concentration ratio) [3] [4] [5] without performing novel experiments, but these QSPR models have not taken into account the time course of CNS distribution. Therefore, there exists an unmet need for approaches to predict drug 1 target-site concentration-time profiles without the need of in vivo animal experiments.
Physiologically based pharmacokinetic (PBPK) modeling represents a promising approach for the prediction of CNS drug concentrations. Previously, such models have been widely used to predict tissue concentrations. 6 The PBPK models typically distinguish between drug-specific and system-specific parameters, therefore, enabling predictions across drugs and species. However, PBPK models for the CNS have been of limited utility due to a lack of relevant physiological details for mechanism of transport across the BBB and BCSFB, and for drug distribution within the CNS. 2 Capturing the physiological compartments, flows, and transport processes in a CNS PBPK model is critically important to predict PK profiles in the CNS. The CNS comprises of multiple key physiological compartments, 2 including brain extracellular fluid (brain ECF ), brain intracellular fluid (brain ICF ), and multiple cerebrospinal fluid (CSF) compartments. The brain ECF and brain ICF compartments are considered highly relevant target sites for CNS drugs, whereas CSF compartments are often used to measure CNS-associated drug concentrations, if brain ECF and brain ICF information cannot be obtained. Furthermore, cerebral blood flow (CBF) and physiological flows within the CNS, such as the brain ECF flow and CSF flows, influence drug distribution across CNS compartments. Next to binding to protein and lipids, pH-dependent distribution in subcellular compartments, such as trapping of basic compounds in lysosomes, needs to be considered. With regard to the transfer processes across the BBB and BCSFB, passive diffusion via the paracellular and transcellular pathways and active transport by influx and/or efflux transporters need to be addressed.
At both BBB and BCSFB barriers, the cells are interconnected by tight junctions, which limit drug exchange via the paracellular pathway. 7 Paracellular and transcellular diffusion depend on the aqueous diffusivity coefficient and membrane permeability of the compound, which can be related to the physicochemical properties. The combination of these transport routes may differ between individual drugs, which complicate the prediction of plasma-brain transport.
System-specific information on physiological parameters can be used in scaling between species. Many of these system-specific parameters can or have been obtained from in vitro and in vivo experiments. Drug-specific parameters can be derived by in vitro and QSPR approaches, and can be used for the scaling between drugs. A comprehensive CNS PBPK model can integrate system-specific and drug-specific parameters to potentially enable the prediction of the brain distribution of drugs without the need to conduct in vivo animal studies.
The purpose of the current work is to develop a comprehensive PBPK model to predict drug concentration-time profiles in the multiple physiologically relevant compartments in the CNS, based on system-specific and drugspecific parameters without the need to generate in vivo data. We specifically consider the prediction of PK profiles in the CNS during pathological conditions, which may have distinct effects on paracellular diffusion, transcellular diffusion, and active transport. Therefore, we include a range of such transport mechanisms in our CNS PBPK model. This model is evaluated using previously published detailed multilevel brain and CSF concentration-time data for 10 drugs with highly diverse physicochemical properties.
MATERIALS AND METHODS
We first empirically modeled plasma PK using available plasma PK data, which was used as the basis for the CNS PBPK model. This CNS model was based entirely on parameters derived from literature and in silico predictions. Model development was performed using NONMEM version 7.3.
Empirical plasma PK model
Plasma PK models were systematically developed using in vivo data with a mixed-effects modeling approach. One, two, and three-compartment models were evaluated. Interindividual variability and interstudy variability were incorporated on each PK parameter using exponential models. Proportional and combined additive-proportional residual error models were considered. Model selection was guided by the likelihood ratio test (P < 0.05), precision of the parameter estimates, and standard goodness of fit plots. 8 CNS PBPK model development A generic PBPK model structure was developed based on the previously published generic multicompartmental CNS distribution model (Figure 1) , 9 which consists of plasma, brain ECF , brain ICF , CSF in the lateral ventricle (CSF LV ), CSF in the third and fourth ventricle (CSF TFV ), CSF in the cisterna magna (CSF CM ), and CSF in the subarachnoid space (CSF SAS ) compartments. We added new components: (1) an acidic subcellular compartment representing lysosomes to account for pH-dependent drug distribution; (2) a brain microvascular compartment (brain MV ) to account for CBF vs. permeability rate-limited kinetics; and (3) separation of passive diffusion at the BBB and BCSFB into its transcellular and paracellular components.
System-specific parameters
Physiological values of the distribution volumes of all the CNS compartments, flows, surface area (SA) of the BBB (SA BBB ), SA of the BCSFB (SA BCSFB ), SA of the total brain cell membrane (BCM; SA BCM ), and the width of BBB (Width BBB ) were collected from literature. The SA BCFSB was divided into SA BCSFB1 , which is a surface area around CSF LV , and SA BCSFB2 , which is a surface area around CSF TFV . The lysosomal volume was calculated based on the volume ratio of lysosomes to brain intracellular fluid of brain parenchyma cells (1:80), 10 and the SA of the lysosome (SA L-YSO ) is calculated by obtaining the lysosome number per cell using the lysosomal volume and the diameter of each lysosome. 11 Transcellular and paracellular diffusion were separately incorporated into the models, therefore, the ratio of SA BBB and SA BCSFB for transcellular diffusion and paracellular diffusion were required for the calculation. Based on electron microscopic cross-section pictures of brain capillary, the length of a single brain microvascular endothelial cell was estimated to be around 17 mm and the length of the intercellular space was estimated to be around 0.03 mm.
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The presence of tight junctions in the intercellular space of the BBB and BCSFB significantly reduces paracellular transport. 7 Therefore, correcting for the effective pore size for paracellular diffusion is important. The transendothelial electrical resistance (TEER) is reported to be around 1,800 X cm 2 at the rat BBB, 13 whereas the TEER is around 20-30 X cm 2 at the rat BCSFB.
14 According to a study on the relationship between TEER and the pore size, 15 the pore size at the BBB and BCSFB can be assumed to be around 0.0011 mm and 0.0028 mm, respectively. Thus, it was expected that 99.8% of total SA BBB and 99.8% of total SA BCSFB is used for the transcellular diffusion (SA BBBt and SA BCSFBt , respectively), whereas 0.006% of total SA BBB and 0.016% of total SA BCSFB are used for paracellular diffusion (SA BBBp and SA BCSFBp , respectively). Note that, due to the presence of tight junction proteins, not all intercellular space can be used for paracellular diffusion.
Drug-specific parameters Aqueous diffusivity coefficient. The aqueous diffusivity coefficient was calculated using the molecular weight of each compound with the following equation 16 :
where Daq is the aqueous diffusivity coefficient (in cm 2 /s) and MW is the molecular weight (in g/mol).
Permeability. Transmembrane permeability was calculated using the log P of each compound with the following equation 17 :
where P transcellular 0 is the transmembrane permeability (in cm/s), log P is the n-octanol lipophilicity value.
Active transport. The impact of the net effect of active transporters on the drug exchange at the BBB and BCSFB was incorporated into the model using asymmetry factors (AFin1-3 and AFout1-3). The AFs were calculated from Kp,uu,brain ECF , Kp,uu,CSF LV (unbound CSF LV -to-plasma concentration ratio) and Kp,uu,CSF CM (unbound CSF CM -toplasma concentration ratio), such that they produced the same Kp,uu values within the PBPK model at the steadystate. Therefore, the AFs were dependent on both the Kp,uu values and the structure and parameters of the PBPK model. If the Kp,uu values were larger than 1 (i.e., net active influx), then AFin1, AFin2, and AFin3 were derived from Kp,uu,brain ECF , Kp,uu,CSF LV , and Kp,uu,CSF CM , respectively, whereas AFout1-3 were fixed to 1. If the Kp,uu values were smaller than 1 (i.e., net active efflux), then AFout1, AFout2, and AFout3 were derived from Kp,uu,brain ECF , Kp,uu,CSF LV , and Kp,uu,CSF CM , respectively, whereas AFin1-3 were fixed to 1. In the Figure 1 The developed model structure. The model consists of a plasma pharmacokinetic (PK) model and a central nervous system (CNS) physiologically based pharmacokinetic (PBPK) model with estimated plasma PK parameters, and system-specific and drugspecific parameters (colors) for CNS. Peripheral compartments 1 and 2 were used in cases where the plasma PK model required them to describe the plasma data adequately. AFin1-3, asymmetry factor into the CNS compartments 1-3; AFout1-3, asymmetry factor out from the CNS compartments 1-3; BBB, blood-brain barrier; BCSFB, blood-cerebrospinal fluid barrier; BF, binding factor; brain ECF analysis, Kp,uu,brain ECF , Kp,uu,CSF LV , and Kp,uu,CSF CM were derived from previous in vivo animal experiments. 9 The steady-state differential equations in the PBPK model were solved using the Maxima Computer Algebra System (http://maxima.sourceforge.net) to obtain algebraic solutions for calculating AFs from the Kp,uu values. The detailed algebraic solutions for each AF are provided in Supplementary Material S1.
Combined system-specific and drug-specific parameters Passive diffusion across the brain barriers. Passive diffusion clearance at the BBB and BCSFB (Q BBB and Q BCSFB , respectively) was obtained from a combination of paracellular and transcellular diffusion, Qp and Qt, respectively (Eq. 3).
where Q BBB/BCSFB represents the passive diffusion clearance at the BBB/BCSFB, Qp BBB/BCSFB represents the paracellular diffusion clearance at the BBB/BCSFB, and Qt BBB/ BCSFB represents the transcellular diffusion clearance at the BBB/BCSFB. The paracellular diffusion clearance was calculated with the aqueous diffusivity coefficient (Daq), Width BBB/BCSFB , and SA BBBp or SA BCSFBp using Eq. 4.
The transcellular diffusion clearance was calculated with the transmembrane permeability and SA BBBt or SA BCSFBt using Eq. 5.
where the factor 1/2 is the correction factor for passage over two membranes instead of one membrane in the transcellular passage.
Active transport across the brain barriers. To take into account the net effect of the active transporters at the BBB and BCSFB, AFs were added on Qt BBB/BCSFB (Eqs. 6 and 7).
where Q BBB/BCSFB_in represents the drug transport clearance from brain MV to brain ECF /CSFs, and Q BBB/BCSFB_out_withoutPHF represents the drug transport clearance from brain ECF / CSFs to brain MV without taking into account the pHdependent kinetics (to be taken into account separately; see below).
Cellular and subcellular distribution. Passive diffusion at the BCM (Q BCM ) and at the lysosomal membrane (Q LYSO ) was described with the transmembrane permeability together with SA BCM or SA LYSO , respectively (Eqs. 8 and 9).
where Q BCM represents the passive diffusion clearance at the BCM, and Q LYSO represents the passive diffusion clearance at the lysosomal membrane.
pH-dependent partitioning. We considered the differences in pH in plasma (pH 7.4) and in relevant CNS compartments, namely brain ECF (pH ECF 7.3), CSF (pH CSF 7.3), brain ICF (pH ICF 7.0), and lysosomes (pH lyso 5.0). 18 The impact of pH differences on the passive diffusion clearance from brain ECF to brain MV (PHF1), from CSF LV to brain MV (PHF2), from CSF TFV to brain MV (PHF3), from brain ECF to brain ICF (PHF4), from brain ICF to brain ECF (PHF5), from brain ICF to lysosomes (PHF6), and from lysosomes to brain ICF (PHF7) were described by pH-dependent factors, which were defined as the ratio of the unionized fraction of each compound at the pH in a particular compartment and the unionized fraction in plasma. The PHFs were calculated from the pKa of each compound and the pH of a particular compartment. The equations are developed using the classical Henderson-Hasselbalch equation, 19, 20 and are based on the assumption that there is no active transport. where PHF base 1-7 are PHF1-7 for basic compounds, PHF acid 1-7 are PHF1-7 for acidic compounds, and 7.4 is the pH in the plasma compartment.
The impact of pH differences on the drug distribution among brain ECF , CSF, brain ICF , and lysosomes was added on Q BCM and Q LYSO using PHFs with the following Eqs. 18-24 based on the assumption that the transport clearance is proportional to the unionized fraction of each compound. In vivo data collection for model evaluation In vivo data obtained from multiple brain locations were used to evaluate the developed model. 9, [23] [24] [25] [26] [27] [28] [29] An overview of experimental design and data for 10 compounds with substantially different physicochemical characteristics is provided in Table 1 .
9,23-29 All data were previously published, except the remoxipride total brain tissue data. General animal surgery procedures, experimental protocol, and bioanalytical methods for remoxipride total brain tissue data are described in Supplementary Material S2, and experimental protocol details for each drug are summarized in Supplementary Table S1 .
Evaluation of the PBPK model The PBPK model performance was evaluated by the comparison of model predictions with the concentration-time profiles in brain ECF , CSF LV , CSF CM , and total brain tissue of 
where Y OBS,ij is the jth observation of the ith subject, Y PRE-D,ij is the jth mean prediction of the ith subject, and N is the number of observations.
RESULTS

Plasma PK model
The estimated parameters for the descriptive plasma PK models were obtained with good precision and summarized in Table 2 . The models describe plasma concentration-time profiles very well for all compounds except risperidone (Supplementary Figure S1) . For remoxipride, a small underprediction was observed at later time points.
CNS PBPK model
The NONMEM model codes for the 10 compounds are provided in Supplementary Material S3-S13. The values of the system-specific and drug-specific parameters are summarized in Tables 3  30-44 and 4, respectively. The combined system-specific and drug-specific parameters are summarized in Table 5 . Overall, the developed generic PBPK model could adequately predict the rat data in brain ECF , CSF LV , CSF CM , and total brain tissue. Figure 2 shows the PE for each compound and each CNS compartment. The PE for risperidone brain ECF and CSF CM showed modest underprediction. For the other drugs, the PEs were distributed within two standard deviations and no specific trends were observed across time, compounds, and CNS locations. The SMAPEs for the model prediction in brain ECF , CSF LV , CSF CM , and total brain tissue were 72%, 71%, 69%, and 91%, respectively, indicating that the model could predict concentration-time profiles in these compartments with less than twofold prediction error. The concentration-time plots of individual predictions vs. observations across drugs and dose levels are provided (Supplementary Figure S1) .
Impact of cerebral blood flow
Cerebral blood flow (Q CBF ) is 1.2 mL/min. 44 Therefore, for strong lipophilic compounds, for instance, quinidine, the drug transport clearance from plasma to the brain ECF (BBB permeability) is limited by Q CBF because Q BBB_in and Q BBB_out of quinidine were 9.1 and 5.1 mL/min, respectively (Tables 3 and 5 ).
Impact of distinct paracellular and transcellular pathways on total diffusion at the BBB, and BCSFB (Q BBB , Q BCSFB1 , and Q BCSFB2 ) The Q BBB , Q BCSFB1 , and Q BCSFB2 were determined by the combination of paracellular and transcellular diffusion in the model. Even though the SA BBBp is very small compared to the SA BBBt (0.006: 99.8), paracellular diffusion had an impact on the values of Q BBB , Q BCSFB1 , and Q BCSFB2 especially for hydrophilic compounds. For instance, the values of transcellular diffusion (Qt BBB ) and paracellular diffusion (Qp BBB ) for methotrexate, which is the most hydrophilic compound in this study, were 0.000080 and 0.087 mL/min, respectively (Table 5) . Thus, the Q BBB of methotrexate was determined mainly by paracellular diffusion. For quinidine, which is the most lipophilic compound in the study, the Q BBB was mainly determined by CBF limited transcellular diffusion (Qt BBB and Qp BBB were 7.6 and 0.10 mL/min, respectively).
Rate limiting drug transport clearance for intra-extracellular exchange (Q BCM_in and Q BCM_out ) The Q BCM_in and Q BCM_out were higher than Q BBB_in and Q BBB_out for acetaminophen, paliperidone, phenytoin, quinidine, raclopride, remoxipride, and risperidone. The Q BCM_in and Q BCM_out are lower than Q BBB_in and Q BBB_out for methotrexate ( Table 5 ). This suggests that the transport clearance from brain MV , via brain ECF , to brain ICF is limited by Q BBB_in and Q BBB_out for acetaminophen, paliperidone, phenytoin, quinidine, raclopride, remoxipride, and risperidone, whereas it is limited by Q BCM_in and Q BCM_out for methotrexate.
Surface area of BCSFB to determine the paracellular and transcellular diffusion clearance around CSF LV and CSF TFV In our model, we assumed that the SA of the BCSFB around CSF LV (SA BCSFB1 ) and CSF TFV (SA BCSFB2 ) are equal in size (50% of the total SA BCSFB for each). The SA is one of the key factors that determine the paracellular and transcellular diffusion clearance across the BCSFB1 and BCSFB2. However, the early-time predictions for CSF LV for acetaminophen, quinidine, and remoxipride indicate an overprediction of the paracellular and transcellular diffusion clearance ( Figure 2 and Supplementary Figure S1 ), suggesting that the SA of BCSFB1 is <50% of the total SA BCSFB .
Impact of active transporters to determine the extent of drug exposure in the CNS compartments Active transporters govern the extent of drug exposure in the brain and CSFs. For most of the compounds, the impact of active transporters among Kp,uu,brain ECF , Kp,uu,CSF LV , and Kp,uu,CSF CM was assumed to be identical, except for methotrexate. Different Kp,uu,CSF LV (0.0066) and Kp,uu,CSF CM (0.0024) were observed for methotrexate, which were taken into account in the PBPK model by asymmetry factors AFout2 and AFout3. The extent of drug entry into the brain and CSF was predicted well for all compounds, except for morphine at the 4 mg/kg dose (Supplementary Figure S1) .
DISCUSSION
The developed CNS PBPK model resulted in adequate predictions of concentration-time courses for 10 diverse drugs Table 2 Parameter estimates for plasma pharmacokinetics of the 10 compounds , and g h is the random effect of the hth study under the assumption of a normal distribution with a mean value of 0 and variance of x in the brain ECF , CSF LV , CSF CM , and total brain tissue with less than twofold prediction error. In comparison, QSPR studies that predict Kp,uu,brain ECF of drugs have similar prediction error magnitudes, even though only one parameter was predicted. 4, 5 Therefore, the twofold prediction error is considered to be a good result.
A small underprediction was observed in brain ECF and CSF CM for risperidone, and in brain ECF for morphine at the 4 mg/kg dose. The underprediction of risperidone brain ECF and CSF CM concentrations (Figure 2) likely results from difficulties in the plasma PK modeling of risperidone, which leads to propagation of an error in the PBPK model. Risperidone plasma PK data appeared to follow a twocompartment PK model but data were insufficient to describe this two-compartment kinetics. The small underprediction for morphine brain ECF profiles at a dosage of 4 mg/kg might be related to a large interstudy variability for morphine, because the predictions for morphine at the other dosage groups could adequately capture the observations (Supplementary Figure S1 and Table S1 ).
This is the first time that the transcellular and paracellular diffusion clearance at the BBB/BCSFB were addressed separately, by using the information of the intercellular space and the effective pore size. As the contribution of these pathways may depend on the condition of the barriers (i.e., in certain disease conditions the tight junctions may become less tight), therefore, assessment of these system-specific parameters is important. From the electron microscopic cross-section picture of brain capillary, 12 the intercellular space was measured to be 0.03 mm, which is comparable to the 0.02 mm width reported. 45 Based on the relationship of the pore size and TEER, which were obtained from in vitro studies, 15 we assumed the effective pore size of the BBB and BCSFB to be 0.0011 mm and 0.0028 mm, respectively. The effective pore size derived for the rat BBB (0.0011 mm) is within the range reported in literature (0.0007-0.0018 mm).
46,47 Therefore, it is reasonable to assume that our estimations for these system-specific parameter values are appropriate. In this study, no compound with sole paracellular transport (such as mannitol) has been used, as no such data were available in literature.
For the PBPK model, the drug-specific parameters were obtained from in silico predictions using the compounds' physicochemical properties, except for AF values. The AF values were calculated using Kp,uu values, as obtained from the previously published in vivo animal experiments. 9 It should be noted that Kp,uu values can also be obtained from several published QSPR models using the compound's physicochemical properties. [3] [4] [5] Unlike previously developed PBPK models for the CNS, 2 our PBPK model contains a number of key relevant physiological processes and compartments.
We discriminated between paracellular and transcellular diffusion processes. The relative impact of the paracellular diffusion on Q BBB or Q BCSFB for each compound varied from around 100% (methotrexate) to 1.3% (quinidine). For hydrophilic compounds, Q BBB and Q BCSFB were impacted most by paracellular diffusion, whereas transcellular diffusion largely determined the Q BBB and Q BCSFB of lipophilic compounds. The separation of the two processes is expected to be meaningful for the prediction of the CNS drug concentrations in disease conditions, because pathophysiological conditions may differently affect paracellular and transcellular diffusion. Based on the lysosome number per cell which was calculated using the total lysosomal volume and diameter of each lysosome (0.5-1.0 mm).
11 Table 4 Drug-specific parameters of the PBPK model CM , unbound CSF CM -to-plasma concentration ratio; Kp, total brain-to-plasma concentration ratio; fu,p, free fraction in plasma; fu,b, free fraction in brain. AFin1-3 and AFout1-3 were calculated from Kp,uu,brain Table 5 Combined parameters of system-specific and drug-specific parameters in the PBPK model We also demonstrated the relevance of considering CBFlimited kinetics on the drug transfer at the BBB. For the lipophilic compounds, Q BBB_in and Q BBB_out are higher than Q CBF , indicating that the drug transfer clearance on the BBB is largely determined by Q CBF .
The importance of the separation between brain ECF and brain ICF compartments was shown. The Q BCM_in and Q BCM_out were either higher or lower than Q BBB_in and Q BBB_out , depending on the molecular weight, the log P, and the pKa of the compound, which led to differences in drug distribution into brain ICF from brain MV .
We identified differences in methotrexate drug concentration in CSF LV and CSF CM . 23 Therefore, it is expected that the expression level (function) of some of the active transporters may be different between the BCSFB around CSF LV and CSF TFV . Methotrexate is known to be a substrate of various transporters, such as RFC1, MRP, BCRP, OATP, and OAT transporters, 23 even though there is no detailed information about their exact location. Therefore, we incorporated this in our model by including Q BCSFB1 and Q BCSFB2 to describe transport for methotrexate. All of the parameters for our CNS PBPK model can be derived from either literature or in silico predictions. Therefore, the model can be used to assess newly developed CNS drugs without in vivo data and contributes to the "refinement, reduction, and replacement" of animals in drug research. Although the reported values of the systemspecific parameters for humans are sparse and variable, 2 theoretically, the model can be scaled to humans by replacing the system-specific parameters to predict target-site concentrations in the human brain, representing an important tool for translational development of new CNS drugs.
